External Quality Assessment Evaluating the Ability of Dutch Clinical Microbiological Laboratories to Identify Candida auris

Buil, Jochem B.; Lee, Henrich A. L. van der; Curfs-Breuker, Ilse; Verweij, Paul E.; Meis, Jacques F.

doi:10.3390/jof5040094

Cited by 11 publications

(14 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Matrix assisted laser desorption ionisations time of flight mass spectrometry (MALDI-TOF MS) is a reliable identification method. Frequently used MAL-DI-TOF platforms are MALDI Biotyper (Bruker-Daltonics) and Vitek MS (bioMérieux) [3][4][5]34]. Importantly, it must be assured that different C. auris spectra are included in the library and laboratories use the most updated versions [34].…”

Section: Microbiological Diagnosticsmentioning

confidence: 99%

Candida auris – recommendations on infection prevention and control measures in Switzerland

et al. 2020

View full text Add to dashboard Cite

Candida auris, a globally emerging pathogen, has been repeatedly introduced into European healthcare settings, leading to large and long-lasting nosocomial outbreaks. The pathogen has already been isolated in Switzerland, requiring clinicians and microbiologists to become alert. This is the first comprehensive guidance document on prevention and control of C. auris in Swiss acute care hospitals. It brings to light the most recent evidence from published original articles and reviews. We emphasise the importance of quickly identifying this yeast by means of screening in order to prevent an outbreak that could be difficult to contain. Key containment strategies include reinforcing early detection, hand hygiene, application of strict contact precautions for colonised and infected patients, and thorough specific environmental cleaning and disinfection.

show abstract

Section: Microbiological Diagnosticsmentioning

confidence: 99%

Candida auris – recommendations on infection prevention and control measures in Switzerland

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Biochemical identification of C. auris isolates by the commercial system API ID 32C (Biomérieux) resulted in misidentification as C. sake or C. intermedia in 83% or 17% of the samples tested, respectively [ 17 ]. Even with matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) correct identification of C. auris was not achieved in all cases [ 17 ], often due to incomplete databases [ 16 , 18 ]. Furthermore, both biochemical and MALDI-TOF based identification require previous cultivation of the pathogen, which may lead to delayed detection [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Two Commercially Available qPCR Kits for the Detection of Candida auris

Sattler

Noster

Brunke

et al. 2021

JoF

Self Cite

View full text Add to dashboard Cite

Candida auris is an emerging pathogen with resistance to many commonly used antifungal agents. Infections with C. auris require rapid and reliable detection methods to initiate successful medical treatment and contain hospital outbreaks. Conventional identification methods are prone to errors and can lead to misidentifications. PCR-based assays, in turn, can provide reliable results with low turnaround times. However, only limited data are available on the performance of commercially available assays for C. auris detection. In the present study, the two commercially available PCR assays AurisID (OLM, Newcastle Upon Tyne, UK) and Fungiplex Candida Auris RUO Real-Time PCR (Bruker, Bremen, Germany) were challenged with 29 C. auris isolates from all five clades and eight other Candida species as controls. AurisID reliably detected C. auris with a limit of detection (LoD) of 1 genome copies/reaction. However, false positive results were obtained with high DNA amounts of the closely related species C. haemulonii, C. duobushaemulonii and C. pseudohaemulonii. The Fungiplex Candida Auris RUO Real-Time PCR kit detected C. auris with an LoD of 9 copies/reaction. No false positive results were obtained with this assay. In addition, C. auris could also be detected in human blood samples spiked with pure fungal cultures by both kits. In summary, both kits could detect C. auris-DNA at low DNA concentrations but differed slightly in their limits of detection and specificity.

show abstract

“…To cope with the healthcare issues arisen from this emerging pathogen, species-level identification of C. auris isolates and their differentiation as susceptible or resistant to the commonly used antifungals agents became mandatory. However, biochemical/enzymatic identification methods are time-consuming and, in the beginning, misidentified C. auris ( Kathuria et al, 2015 ); whereas MALDI-TOF mass spectrometry (MS) based identification was not optimal ( Buil et al, 2019 ) until when MALDI-TOF MS databases were enriched with C. auris specific mass spectrum profiles ( Girard et al, 2016 ; Bao et al, 2018 ). Of course, molecular methods such as C. auris colony-specific PCR and DNA sequencing ( Kordalewska et al, 2017 ; Valentin et al, 2018 ) are efficient but less rapid than those based on the MALDI-TOF MS analysis.…”

Section: Introductionmentioning

confidence: 99%

Are We Ready for Nosocomial Candida auris Infections? Rapid Identification and Antifungal Resistance Detection Using MALDI-TOF Mass Spectrometry May Be the Answer

Carolis

Marchionni

Rosa

et al. 2021

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

The occurrence of multidrug-resistant Candida auris isolates and the increased mortality associated with invasive infections or outbreaks due to this Candida species have been reported in many healthcare settings. Therefore, accurate and rapid identification at the species level of clinical C. auris isolates as well as their timely differentiation as susceptible or resistant to antifungal drugs is mandatory. Aims of the present study were to implement the MALDI-TOF mass spectrometry (MS) Bruker Daltonics Biotyper® database with C. auris spectrum profiles and to develop a fast and reproducible MS assay for detecting anidulafungin (AFG) resistance in C. auris isolates. After creation of main C. auris spectra, a score-oriented dendrogram was generated from hierarchical cluster analysis, including spectra of isolates from C. auris and other Candida (C. glabrata, C. guilliermondii, C. haemulonii, C. lusitaniae, and C. parapsilosis) or non-Candida (Rhodotorula glutinis) species. Cluster analysis allowed to group and classify the isolates according to their species designation. Then, a three-hour incubation antifungal susceptibility testing (AFST) assay was developed. Spectra obtained at null, intermediate, or maximum AFG concentrations were used to create composite correlation index matrices for eighteen C. auris isolates included in the study. All six resistant C. auris isolates were detected as resistant whereas 11 of 12 susceptible C. auris isolates were detected as susceptible by the MS-AFST assay. In conclusion, our MS-based assay offers the possibility of rapidly diagnosing and appropriately treating patients with C. auris infection.

show abstract

External Quality Assessment Evaluating the Ability of Dutch Clinical Microbiological Laboratories to Identify Candida auris

Cited by 11 publications

References 49 publications

Candida auris – recommendations on infection prevention and control measures in Switzerland

Candida auris – recommendations on infection prevention and control measures in Switzerland

Comparison of Two Commercially Available qPCR Kits for the Detection of Candida auris

Are We Ready for Nosocomial Candida auris Infections? Rapid Identification and Antifungal Resistance Detection Using MALDI-TOF Mass Spectrometry May Be the Answer

Contact Info

Product

Resources

About